Published in Blood Weekly, August 31st, 2006
"The use of HDAraC during induction may improve outcomes in patients with AML compared with standard-dose AraC (SDAraC). The objective of this review was to assess the impact of HDAraC during induction therapy for patients with AML based on results from randomized trials," scientists in Germany reported.
"All randomized trials in the field were identified by using a pre-defined search strategy," explained W. Kern...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.